Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
about
Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.Targeted therapies in breast cancer: New challenges to fight against resistance.The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.Two is better than one; toward a rational design of combinatorial therapy.Advances in decoding breast cancer brain metastasis.Brain metastasis: Unique challenges and open opportunities.CDK4/6 inhibition triggers anti-tumour immunity.Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.Comprehensive molecular biomarker identification in breast cancer brain metastases.hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases.Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Species classifier choice is a key consideration when analysing low-complexity food microbiome data.Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours
P2860
Q30238959-AAAD921F-9465-4382-9C82-003E00776944Q37743048-6446E01D-3D0F-495D-A203-31D6F622A70EQ38766447-6DC7076B-9E4C-411A-BBCD-C68B4CA3398CQ38926952-D729CAD6-9128-4126-AFFA-36000EB918F3Q39016244-31CDF593-1332-4B14-BA21-07A017996DBAQ39035128-4EF2229F-3C88-4B08-920D-ACF416D548A2Q40081387-39CB6E62-D254-44DE-99B2-56BEF62901CFQ43494911-8AD9EDFB-7438-4E5E-B940-EB806E855333Q47098306-417697F2-9342-45C6-9AB4-1E1AEBFF55C5Q47116845-BD42729B-33F3-496F-8713-B805DCBA357FQ47141003-64449464-DE85-4E69-9EEE-EDA74D5747DAQ47630528-8A6D2237-C0D8-434B-BCA1-160D7889D62AQ50043843-687549FE-B999-4F48-9B01-FFF40E5419FDQ52350222-D6945704-FA50-4A6C-BD45-9131441B958BQ55417928-A2697326-9035-46DF-A20B-13A4148DA9A7Q58611476-B2812865-7631-4F32-8C54-8008F01B5D54
P2860
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination inhibition of PI3K ...... reast cancer brain metastases.
@en
Combination inhibition of PI3K ...... reast cancer brain metastases.
@nl
type
label
Combination inhibition of PI3K ...... reast cancer brain metastases.
@en
Combination inhibition of PI3K ...... reast cancer brain metastases.
@nl
prefLabel
Combination inhibition of PI3K ...... reast cancer brain metastases.
@en
Combination inhibition of PI3K ...... reast cancer brain metastases.
@nl
P2093
P2860
P50
P356
P1433
P1476
Combination inhibition of PI3K ...... reast cancer brain metastases.
@en
P2093
Azra H Ligon
Brian M Alexander
Elizabeth B Claus
Eric P Winer
Eugenio Marco
Hanbing Guo
Ian E Krop
J Dirk Iglehart
Jean J Zhao
P2860
P2888
P304
P356
10.1038/NM.4120
P407
P577
2016-06-06T00:00:00Z
P6179
1021579715